论文部分内容阅读
如果1型人类免疫缺陷症病毒(HIV-1)包膜蛋白诱导的免疫应答对免疫显性变异性表位具有特异性,那么,包膜蛋白的抗原性变异可能会限制其在疫苗中的应用。作者制备了含有来源于两个HIV-1变异株的免疫应答的能力进行了评估。
If the immune response induced by the envelope protein of type 1 human immunodeficiency virus (HIV-1) is specific for an immunodominant, variant epitope, then the antigenic variation of the envelope protein may limit its use in vaccines . The authors prepared an assessment of the ability to contain an immune response derived from two HIV-1 mutants.